| Pharmaceutical Information |
| Drug Name |
Pegvisomant |
| Drug ID |
BADD_D01699 |
| Description |
Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity. |
| Indications and Usage |
Pegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly. |
| Marketing Status |
approved |
| ATC Code |
H01AX01 |
| DrugBank ID |
DB00082
|
| KEGG ID |
D05394
|
| MeSH ID |
C406545
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0D6VE
|
| NDC Product Code |
0009-7166; 59267-5376; 59267-9301; 59267-9201; 0009-7168; 59267-5201; 59267-9401; 0009-7188; 0009-7200; 64052-001; 0009-7199 |
| UNII |
N824AOU5XV
|
| Synonyms |
pegvisomant | B2036-PEG | B-2036 PEG | Somavert |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
218620-50-9 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
